Arcus Biosciences Inc (RCUS) - Total Assets
Based on the latest financial reports, Arcus Biosciences Inc (RCUS) holds total assets worth $974.00 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Arcus Biosciences Inc for net asset value and shareholders' equity analysis.
Arcus Biosciences Inc - Total Assets Trend (2016–2024)
This chart illustrates how Arcus Biosciences Inc's total assets have evolved over time, based on quarterly financial data.
Arcus Biosciences Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Arcus Biosciences Inc's total assets of $974.00 Million consist of 88.4% current assets and 11.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 13.0% |
| Accounts Receivable | $25.00 Million | 2.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Arcus Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Arcus Biosciences Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Arcus Biosciences Inc's current assets represent 88.4% of total assets in 2024, a decrease from 90.9% in 2016.
- Cash Position: Cash and equivalents constituted 13.0% of total assets in 2024, down from 59.4% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 2.2% of total assets.
Arcus Biosciences Inc Competitors by Total Assets
Key competitors of Arcus Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.62 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥7.26 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥38.02 Billion |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180
|
China | CN¥11.69 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $504.60 Million |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $563.83 Million |
Arcus Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.65 | 5.24 | 6.05 |
| Quick Ratio | 3.65 | 5.24 | 6.11 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $622.00 Million | $912.00 Million | $614.15 Million |
Arcus Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Arcus Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.37 |
| Latest Market Cap to Assets Ratio | 2.07 |
| Asset Growth Rate (YoY) | 5.0% |
| Total Assets | $1.15 Billion |
| Market Capitalization | $2.38 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Arcus Biosciences Inc's assets at a significant premium (2.07x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Arcus Biosciences Inc's assets grew by 5.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Arcus Biosciences Inc (2016–2024)
The table below shows the annual total assets of Arcus Biosciences Inc from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.15 Billion | +5.02% |
| 2023-12-31 | $1.09 Billion | -18.59% |
| 2022-12-31 | $1.34 Billion | -15.51% |
| 2021-12-31 | $1.59 Billion | +106.13% |
| 2020-12-31 | $772.29 Million | +280.23% |
| 2019-12-31 | $203.11 Million | -26.12% |
| 2018-12-31 | $274.93 Million | +44.33% |
| 2017-12-31 | $190.49 Million | +73.64% |
| 2016-12-31 | $109.70 Million | -- |
About Arcus Biosciences Inc
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develop… Read more